- Report
- August 2023
- 112 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- December 2023
- 76 Pages
Global
From €950EUR$995USD£796GBP
- Report
- December 2023
- 265 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- September 2023
- 114 Pages
Global
From €2815EUR$2,950USD£2,359GBP
- Report
- September 2023
- 194 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- February 2023
Global
€4990EUR$5,601USD£4,327GBP
- Report
- March 2021
- 137 Pages
Global
From €4676EUR$4,900USD£3,918GBP
- Report
- January 2021
- 109 Pages
Global
€3990EUR$4,479USD£3,460GBP
- Report
- March 2025
- 79 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- November 2024
- 78 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- January 2024
- 101 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- December 2023
- 102 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- July 2024
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Report
- December 2024
- 348 Pages
Global
From €2534EUR$2,655USD£2,123GBP
- Report
- December 2024
- 90 Pages
United States
From €2078EUR$2,177USD£1,741GBP
- Report
- November 2024
- 150 Pages
United Kingdom
From €1900EUR$1,991USD£1,592GBP
- Report
- November 2024
- 130 Pages
Asia Pacific
From €1774EUR$1,859USD£1,487GBP
- Report
- November 2024
- 90 Pages
Australia
From €1774EUR$1,859USD£1,487GBP
- Report
- July 2022
- 234 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Book
- February 2025
- 432 Pages

In the landscape of vaccines, mRNA (messenger RNA) vaccines represent a novel technology that has garnered substantial attention for its role in rapid vaccine development. These vaccines operate by instructing cells to produce a protein that triggers an immune response without using a live virus. This innovative approach stands out for its ability to be developed and scaled up swiftly in response to infectious diseases, offering a flexible platform for vaccine creation. While traditional vaccine development may take years of research and testing, mRNA vaccines can be designed once the genetic information of a pathogen is known.
The adoption of mRNA vaccines has been driven by their potential to address a broad spectrum of diseases beyond just infectious agents. Research is being conducted into their applicability in treating and preventing cancers, genetic disorders, and autoimmune diseases. This expansion of mRNA technology into various medical domains has contributed to the diversification of the vaccine industry.
Several prominent companies are active in the mRNA vaccines market, shaping its trajectory with their research and development efforts. Notable firms include Moderna, Pfizer in collaboration with BioNTech, and CureVac. These companies have invested heavily in mRNA technology, leading to advances that have solidified their positions as key players in the pharmaceutical and biotechnology sectors. Show Less Read more